Search Results Search Sort by RelevanceMost Recent Policy Forum May 2022 What Should Dietary Supplement Oversight Look Like in the US? Elizabeth Richardson, MSc, Farzana Akkas, MSc, and Amy B. Cadwallader, PhD Statutory limitations prevent the FDA from effectively regulating dietary supplements and have generated numerous calls for reform. AMA J Ethics. 2022;24(5):E402-409. doi: 10.1001/amajethics.2022.402. Policy Forum May 2022 Which Features of Dietary Supplement Industry, Product Trends, and Regulation Deserve Physicians’ Attention? Amy B. Cadwallader, PhD and AMA Council on Science and Public Health Illegal, fraudulent, adulterated, or improperly labeled products should be regarded as sources of possible clinical and ethical harm to patients. AMA J Ethics. 2022;24(5):E410-418. doi: 10.1001/amajethics.2022.410. Policy Forum Nov 2022 If Patients Don’t Use Available Health Service Pricing Information, Is Transparency Still Important? Christopher Whaley, PhD and Austin Frakt, PhD Online tools intended to make health care purchasing resemble “consumerism” have had little effect on improving transparency for patients. AMA J Ethics. 2022;24(11):E1056-1062. doi: 10.1001/amajethics.2022.1056. Policy Forum Nov 2022 Informed Consent as a Means of Acknowledging and Avoiding Financial Toxicity as Iatrogenic Harm Kevin Schulman, MD and Barak Richman, PhD, JD Negative health consequences from costly care are referred to as financial toxicity and should be included in informed consent discussions. AMA J Ethics. 2022;24(11):E1063-1068. doi: 10.1001/amajethics.2022.1063. Policy Forum Jun 2003 Diversity and the Road to the "Land of Best Care" Lonnie R. Bristow, MD The author discusses why the U.S. needs ethnically diverse medical professionals in order to stay competitive in the global economy. Virtual Mentor. 2003;5(6):225-227. doi: 10.1001/virtualmentor.2003.5.6.pfor1-0306.
Policy Forum May 2022 What Should Dietary Supplement Oversight Look Like in the US? Elizabeth Richardson, MSc, Farzana Akkas, MSc, and Amy B. Cadwallader, PhD Statutory limitations prevent the FDA from effectively regulating dietary supplements and have generated numerous calls for reform. AMA J Ethics. 2022;24(5):E402-409. doi: 10.1001/amajethics.2022.402.
Policy Forum May 2022 Which Features of Dietary Supplement Industry, Product Trends, and Regulation Deserve Physicians’ Attention? Amy B. Cadwallader, PhD and AMA Council on Science and Public Health Illegal, fraudulent, adulterated, or improperly labeled products should be regarded as sources of possible clinical and ethical harm to patients. AMA J Ethics. 2022;24(5):E410-418. doi: 10.1001/amajethics.2022.410.
Policy Forum Nov 2022 If Patients Don’t Use Available Health Service Pricing Information, Is Transparency Still Important? Christopher Whaley, PhD and Austin Frakt, PhD Online tools intended to make health care purchasing resemble “consumerism” have had little effect on improving transparency for patients. AMA J Ethics. 2022;24(11):E1056-1062. doi: 10.1001/amajethics.2022.1056.
Policy Forum Nov 2022 Informed Consent as a Means of Acknowledging and Avoiding Financial Toxicity as Iatrogenic Harm Kevin Schulman, MD and Barak Richman, PhD, JD Negative health consequences from costly care are referred to as financial toxicity and should be included in informed consent discussions. AMA J Ethics. 2022;24(11):E1063-1068. doi: 10.1001/amajethics.2022.1063.
Policy Forum Jun 2003 Diversity and the Road to the "Land of Best Care" Lonnie R. Bristow, MD The author discusses why the U.S. needs ethnically diverse medical professionals in order to stay competitive in the global economy. Virtual Mentor. 2003;5(6):225-227. doi: 10.1001/virtualmentor.2003.5.6.pfor1-0306.